Abstract
In a landmark publication of 1971, Folkman proposed antiangiogenesis as a potential target in cancer biology [1]. Over the past 30 years most research on tumor angiogenesis has been aimed at inhibiting the process of tumorinduced vessel formation. The first angiogenesis inhibitor, bevacizumab, was approved by the Food and Drug Administration in 2004 for the treatment of metastatic carcinoma of the colon-rectum. Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
Keywords: Angiogenesis, antiangiogenesis, history of medicine, tumor growth
Current Pharmaceutical Design
Title: The Discovery of Antiangiogenic Molecules: A Historical Review
Volume: 15 Issue: 4
Author(s): Domenico Ribatti
Affiliation:
Keywords: Angiogenesis, antiangiogenesis, history of medicine, tumor growth
Abstract: In a landmark publication of 1971, Folkman proposed antiangiogenesis as a potential target in cancer biology [1]. Over the past 30 years most research on tumor angiogenesis has been aimed at inhibiting the process of tumorinduced vessel formation. The first angiogenesis inhibitor, bevacizumab, was approved by the Food and Drug Administration in 2004 for the treatment of metastatic carcinoma of the colon-rectum. Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
Export Options
About this article
Cite this article as:
Ribatti Domenico, The Discovery of Antiangiogenic Molecules: A Historical Review, Current Pharmaceutical Design 2009; 15 (4) . https://dx.doi.org/10.2174/138161209787315855
DOI https://dx.doi.org/10.2174/138161209787315855 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry <i>In silico</i> and <i>In vitro</i> Investigation of a Likely Pathway for Anti-Cancerous Effect of Thrombocidin-1 as a Novel Anticancer Peptide
Protein & Peptide Letters Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Association of GRP78, HIF-1α and BAG3 Expression with the Severity of Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry